Abstract: The present invention provides methods and compositions related to the discovery of molecules capable of both inducing an immune response to an antigen in a mammal and also effecting clearance of the antigen, with such molecules comprising a first moiety comprising an antigen binding portion which binds specifically to complement receptor 1 (CR1) and does not substantially bind to complement receptor 2 (CR2), linked to a second moiety which comprises the antigen or binds to the antigen. Methods of producing such molecules and their therapeutic and/or prophylactic uses are also featured.

Abstract: The invention relates to a bispecific molecule comprising a first recognition binding moeity that binds a Cab-like receptor cross-linked using a poly-(ethylene glycol) (“PEG”) linker with one or more second recognition binding moieties that bind a molecule. The invention also relates to methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules.

Abstract: The invention provides a bispecific molecule comprising an antibody that binds a C3b-like to one or more antigen-binding antibody fragments, each of which binds an antigenic molecule. The invention also provides methods of producing such bispecific molecules and to therapeutic uses of such bispecific molecules. The invention further provides bispecific molecules in which the antigen-binding antibody fragment binds the protective antigen protein of Bacillus anthracis (Anthrax) exotoxin for treatment of Anthrax infection.

Abstract: The present invention provide a bispecific molecule comprising an antibody that binds a C3b-like receptor linked to one or more non-neutralizing antigen-binding antibodies or fragments thereof. The present invention also provides methods to identify non-neutralizing antibodies, and particularly, to identify enhancing antibodies.